A Phase 4 interventional study of Sildenafil citrate and Sildenafil citrate in Pulmonary Arterial Hypertension, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Terminated at 46 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-22.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing sildenafil in Pulmonary Arterial Hypertension — 1 open to participants now, 1 under way, 1 of them phase 3. sildenafil · Pulmonary Arterial Hypertension.
Among the 18 studies testing sildenafil in Pulmonary Arterial Hypertension, this one is the 4th largest by enrollment, is one of 2 that started in 2008, is one of 6 in phase 4, and was the 6th registered.
700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 140 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →1 of the 18 studies testing sildenafil in Pulmonary Arterial Hypertension is open now, in 1 country. Recruiting first, the newest first:
Silvia Ulrich · Sites in Switzerland
Ages 18–80
By country, each count listing its studies:
sildenafil: first FDA approval 1998 (VIAGRA), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 1 · Phase 3 8 · Phase 4 6
First in 2002; this study’s year is marked. 2 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 130 is above the median of 40 across 477 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 23 across the 18 interventional studies. Of the 14 that completed or were terminated, 10 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 18 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
14 studies in Pulmonary Arterial Hypertension by Viatris Inc.: none open now, none under way, none of them phase 3. Of 9 finished, 8 (89%) have results posted.
Among the 14 studies in Pulmonary Arterial Hypertension by Viatris Inc., this one is the only one that started in 2008, is one of 4 in phase 4, and was the 4th registered.
Viatris Inc.’s Pulmonary Arterial Hypertension studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing sildenafil in Pulmonary Arterial Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Viatris Inc.’s 14 in Pulmonary Arterial Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To demonstrate a dose response for 1 mg, 5 mg and 20 mg TID oral sildenafil for the treatment of subjects with PAH.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Sildenafil citrate
Drug: Sildenafil citrate
Drug: Sildenafil citrate
Open label extension from week 12 to week 24.
Drug: Sildenafil citrate
oral, 20 mg, tid
oral 1 mg, tid
oral 5 mg, tid
oral 20 mg, tid
Change From Baseline in the Total Distance Walked During 6-Minute Walk Test (6MWT) at Week 12
6 MWT was the distance that a participant could walk in 6 minutes. Participants were asked to perform the test at a pace that was comfortable to them, with as many breaks as they needed. Continuous pulse oximetry was conducted during the test for safety.
Time frame: Baseline and Week 12
Change From Baseline in Mean Pulmonary Arterial Pressure (mPAP) at Week 12
mPAP was measured using a pressure transducer positioned at the mid-axillary line.
Time frame: Baseline and Week 12
Number of Participants With Clinical Worsening
Clinical worsening was defined as death; or lung transplantation; or hospitalization due to pulmonary hypertension; or initiation of prostacyclin therapy; or initiation of endothelin receptor antagonist therapy. (PAH=pulmonary arterial hypertension) Due to very low number of events of clinical worsening reported, the median days to clinical worsening could not be estimated.
Time frame: Baseline through Week 12
Number of Participants With Change From Baseline in PAH Criteria for Functional Capacity and Therapeutic Class at Week 12
Pulmonary arterial hypertension (PAH) Criteria for WHO Class: Class I (Participants without resulting limitation of physical activity);Class II (Participants with slight limitation of physical activity though comfortable at rest);Class III (Participants with marked limitation of physical activity,though comfortable at rest);Class IV(Participants with inability to carry out any physical activity without symptoms,manifest signs of right heart failure; dyspnoea and/or fatigue may even be present at rest; and discomfort is increased by any physical activity).
Time frame: Baseline and Week 12
Change From Baseline in B-Type Natriuretic Peptide (BNP) at Week 12
BNP is a non-invasive biomarker and an indicator of progression of PAH/ right ventricular dysfunction in participants with PAH.
Time frame: Baseline and Week 12
Change From Baseline in Pro-BNP at Week 12
Pro- BNP which is a precursor of BNP, is a non-invasive biomarker and an indicator of progression of PAH / RV dysfunction in participants with PAH.
Time frame: Baseline and Week 12
Change From Baseline in TAPSE Measurement at Week 12
Tricuspid annular plane systolic excursion (TAPSE) was measured as the total displacement of the tricuspid annulus in cm from end diastole to end systole.TAPSE is an indicator of progression of PAH /right ventricular dysfunction. The baseline data for 33 participants were measured incorrectly and the results from the 33 participants (both baseline and post-baseline) were excluded from the analysis.
Time frame: Baseline and Week 12
Change From Baseline in BORG Dyspnoea Score at Week 12
BORG dyspnoea scale is a 10-point scale where following scores stands for severity of dyspnoea: 0 (no breathlessness at all); 0.5 (very very slight \[just noticeable\]); 1 (very slight); 2 (slight breathlessness); 3 (moderate); 4 (some what severe); 5 (severe breathlessness); 7 (very severe breathlessness); 9 (very very severe \[almost maximum\] and 10 (maximum).
Time frame: Baseline and Week 12
| Milestone | Sildenafil 1 mg | Sildenafil 5 mg | Sildenafil 20 mg |
|---|---|---|---|
| Started | 42 | 43 | 45 |
| Treated | 41 | 43 | 45 |
| Completed | 36 | 38 | 39 |
| Not completed | 6 | 5 | 6 |
| Withdrew: Death | 1 | 0 | 0 |
| Withdrew: No longer willing to participate | 2 | 1 | 1 |
| Withdrew: Other | 0 | 2 | 0 |
| Withdrew: Study terminated by sponsor | 1 | 1 | 2 |
| Withdrew: Adverse event | 1 | 1 | 3 |
| Withdrew: Not treated | 1 | 0 | 0 |
| Milestone | Sildenafil 1 mg | Sildenafil 5 mg | Sildenafil 20 mg |
|---|---|---|---|
| Started | 36 | 38 | 39 |
| Completed | 27 | 31 | 32 |
| Not completed | 9 | 7 | 7 |
| Withdrew: Lost to follow-up | 1 | 0 | 1 |
| Withdrew: No longer willing to participate | 0 | 1 | 1 |
| Withdrew: Other | 3 | 1 | 1 |
| Withdrew: Protocol violation | 1 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 4 | 5 | 4 |
6 MWT was the distance that a participant could walk in 6 minutes. Participants were asked to perform the test at a pace that was comfortable to them, with as many breaks as they needed. Continuous pulse oximetry was conducted during the test for safety.
| Meters | Sildenafil 1 mg | Sildenafil 5 mg | Sildenafil 20 mg |
|---|---|---|---|
| Change From Baseline in the Total Distance Walked During 6-Minute Walk Test (6MWT) at Week 12 | 14.21 (0.41 to 28.00) | 40.75 (25.16 to 56.34) | 38.36 (23.77 to 52.94) |
mPAP was measured using a pressure transducer positioned at the mid-axillary line.
| mmHg | Sildenafil 1 mg | Sildenafil 5 mg | Sildenafil 20 mg |
|---|---|---|---|
| Change From Baseline in Mean Pulmonary Arterial Pressure (mPAP) at Week 12 | -1.73 (-5.99 to 2.54) | -3.44 (-5.87 to -1.00) | -3.29 (-6.05 to -0.52) |
Clinical worsening was defined as death; or lung transplantation; or hospitalization due to pulmonary hypertension; or initiation of prostacyclin therapy; or initiation of endothelin receptor antagonist therapy. (PAH=pulmonary arterial hypertension) Due to very low number of events of clinical worsening reported, the median days to clinical worsening could not be estimated.
| Participants | Sildenafil 1 mg | Sildenafil 5 mg | Sildenafil 20 mg |
|---|---|---|---|
| death | 1 | 1 | 0 |
| lung transplantation | 0 | 0 | 0 |
| hospitalisation due to pulmonary hypertension | 1 | 0 | 2 |
| PAH deterioration requiring therapy | 0 | 0 | 0 |
| receptor antagonist therapy | 0 | 1 | 0 |
Pulmonary arterial hypertension (PAH) Criteria for WHO Class: Class I (Participants without resulting limitation of physical activity);Class II (Participants with slight limitation of physical activity though comfortable at rest);Class III (Participants with marked limitation of physical activity,though comfortable at rest);Class IV(Participants with inability to carry out any physical activity without symptoms,manifest signs of right heart failure; dyspnoea and/or fatigue may even be present at rest; and discomfort is increased by any physical activity).
| Participants | Sildenafil 1 mg | Sildenafil 5 mg | Sildenafil 20 mg |
|---|---|---|---|
| Worsened 2 Classes | 0 | 0 | 0 |
| Worsened 1 Class | 1 | 3 | 2 |
| No Change | 35 | 27 | 35 |
| Improved 1 Class | 4 | 10 | 6 |
| Improved 2 Classes | 1 | 0 | 0 |
| Missing | 0 | 3 | 2 |
BNP is a non-invasive biomarker and an indicator of progression of PAH/ right ventricular dysfunction in participants with PAH.
| pg/mL | Sildenafil 1 mg | Sildenafil 5 mg | Sildenafil 20 mg |
|---|---|---|---|
| Change From Baseline in B-Type Natriuretic Peptide (BNP) at Week 12 | -6.28 (-80.75 to 68.19) | -53.46 (-99.98 to -6.94) | -97.42 (-161.45 to -33.39) |
Pro- BNP which is a precursor of BNP, is a non-invasive biomarker and an indicator of progression of PAH / RV dysfunction in participants with PAH.
| pg/mL | Sildenafil 1 mg | Sildenafil 5 mg | Sildenafil 20 mg |
|---|---|---|---|
| Change From Baseline in Pro-BNP at Week 12 | -111.53 (-507.68 to 284.63) | -306.76 (-523.82 to -89.70) | -428.54 (-676.74 to -180.34) |
Tricuspid annular plane systolic excursion (TAPSE) was measured as the total displacement of the tricuspid annulus in cm from end diastole to end systole.TAPSE is an indicator of progression of PAH /right ventricular dysfunction. The baseline data for 33 participants were measured incorrectly and the results from the 33 participants (both baseline and post-baseline) were excluded from the analysis.
| cm | Sildenafil 1 mg | Sildenafil 5 mg | Sildenafil 20 mg |
|---|---|---|---|
| Change From Baseline in TAPSE Measurement at Week 12 | 0.08 (-0.04 to 0.19) | 0.17 (0.05 to 0.29) | -0.02 (-0.15 to 0.10) |
BORG dyspnoea scale is a 10-point scale where following scores stands for severity of dyspnoea: 0 (no breathlessness at all); 0.5 (very very slight \[just noticeable\]); 1 (very slight); 2 (slight breathlessness); 3 (moderate); 4 (some what severe); 5 (severe breathlessness); 7 (very severe breathlessness); 9 (very very severe \[almost maximum\] and 10 (maximum).
| Units on a scale | Sildenafil 1 mg | Sildenafil 5 mg | Sildenafil 20 mg |
|---|---|---|---|
| Change From Baseline in BORG Dyspnoea Score at Week 12 | -0.28 (-0.76 to 0.20) | -0.89 (-1.35 to -0.43) | -0.43 (-0.94 to 0.08) |
Collected over 24 Weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sildenafil 1 mg | 1/41 (2.4%) | 6/41 (14.6%) | 21/41 (51.2%) |
| Sildenafil 5 mg | 1/43 (2.3%) | 3/43 (7%) | 22/43 (51.2%) |
| Sildenafil 20 mg | 0/45 (0%) | 5/45 (11.1%) | 22/45 (48.9%) |
| Event | Sildenafil 1 mg | Sildenafil 5 mg | Sildenafil 20 mg |
|---|---|---|---|
| Right ventricular failureCardiac disorders | 0/41 | 0/43 | 2/45 |
| Atrial flutterCardiac disorders | 1/41 | 0/43 | 0/45 |
| Cor pulmonaleCardiac disorders | 1/41 | 0/43 | 0/45 |
| HepatitisHepatobiliary disorders | 1/41 | 0/43 | 0/45 |
| Lower respiratory tract infectionInfections and infestations | 1/41 | 0/43 | 0/45 |
| PneumoniaInfections and infestations | 1/41 | 0/43 | 0/45 |
| Atrial flutterCardiac disorders | 1/41 | 0/43 | 0/45 |
| Cor pulmonaleCardiac disorders | 1/41 | 0/43 | 0/45 |
| HepatitisHepatobiliary disorders | 1/41 | 0/43 | 0/45 |
| Lower respiratory tract infectionInfections and infestations | 1/41 | 0/43 | 0/45 |
| Event | Sildenafil 1 mg | Sildenafil 5 mg | Sildenafil 20 mg |
|---|---|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/41 | 4/43 | 3/45 |
| FatigueGeneral disorders | 3/41 | 1/43 | 0/45 |
| DizzinessNervous system disorders | 3/41 | 2/43 | 2/45 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/41 | 3/43 | 3/45 |
| HeadacheNervous system disorders | 2/41 | 3/43 | 3/45 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 1/41 | 3/43 | 0/45 |
| HeadacheNervous system disorders | 1/41 | 1/43 | 3/45 |
| NasopharyngitisInfections and infestations | 2/41 | 1/43 | 3/45 |
| Back painMusculoskeletal and connective tissue disorders | 1/41 | 1/43 | 3/45 |
| FatigueGeneral disorders | 2/41 | 1/43 | 0/45 |
| Age, Continuous(Years) | Sildenafil 1 mg | Sildenafil 5 mg | Sildenafil 20 mg | Total |
|---|---|---|---|---|
| Mean | 42.5 ± 16.5 | 44.4 ± 17.4 | 46.4 ± 17.7 | 44.5 ± 17.2 |
| Sex: Female, Male(Participants) | Sildenafil 1 mg | Sildenafil 5 mg | Sildenafil 20 mg | Total |
|---|---|---|---|---|
| Female | 28 | 33 | 26 | 87 |
| Male | 13 | 10 | 19 | 42 |
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Apr 2008 to primary completion in May 2010, 25 months.
Results were first posted in May 2011, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sildenafil
Pulmonary Arterial Hypertension →
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →